Author: Ken Dropiewski

Caption Health Receives $4.95M Grant to Develop AI-Guided Lung Ultrasound System

Grant from the Bill & Melinda Gates Foundation will be leveraged to create new AI technology that allows medical professionals without prior ultrasound experience to perform lung ultrasounds, expanding access to quality medical care BRISBANE, Calif., Nov. 12, 2020 /PRNewswire/ — Caption Health, a leading medical artificial intelligence (AI) company, today announced that […]

HeartFlow Appoints Cybersecurity Expert Julie Cullivan to its Board of Directors

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., a leader in revolutionizing precision heartcare, has named Julie Cullivan, Chief Information Officer of Forescout Technologies, Inc., the leader in Enterprise of Things security, to its Board of Directors, effective November 19, 2020. “Julie’s long-time leadership in the technology and cybersecurity industry will provide substantial […]

Liquidia Closes Acquisition of RareGen

Merger Reinforces Company’s Commitment to Patients with PAH Paul Manning and Roger Jeffs Join Liquidia Corporation Board of Directors RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that it […]

Sequana Medical Announces Positive Interim Data From North American Pivotal alfapump® Study (POSEIDON)

Results from first 13 patients in Roll-In Cohort showed over 90% reduction in mean frequency of therapeutic paracentesis versus baseline Indication of rapid and persistent clinically relevant improvement in patients’ quality of life Safety profile in line with expectations Interim data of the full Roll-In Cohort expected in H1 2021 Conference call with live webcast presentation today at 02:00 pm CET / 08:00 am EDT GHENT, Belgium, […]

CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts

MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) — CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s long-term growth plan. Jared Oasheim, who joined CVRx in 2015, was promoted from Vice President of Finance to Chief Financial Officer (CFO). He […]

Medicure Announces Settlement of Patent Infringement Action

WINNIPEG, MB, Nov. 18, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announces that its subsidiary, Medicure International Inc., has settled its ongoing patent infringement action against Nexus Pharmaceuticals, Inc. (“Nexus”) in the U.S. District Court for the Northern District of Illinois, which […]

Quanterix Appoints William Geist as Chief Operating Officer

Geist brings operational experience to Quanterix as the company scales to support rapid growth and commercial success BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has named William Geist to the position of chief operating officer (COO), […]

Zynex Ranked 13th in Revenue Growth Among Medical Device Companies

ENGLEWOOD, Colo., Nov. 19, 2020 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced it has been ranked 13th in revenue growth among all medical device companies in the U.S. and Canada on Deloitte’s […]

Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

– In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular disease – Recurrent cardiovascular events in people with type 2 diabetes are […]

Novoheart Holdings Inc. has Closed its Going-Private Transaction

VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH) is pleased to announce that the previously announced acquisition by Novomed Limited (the “Purchaser”), a company beneficially owned by entities controlled by Prof. Ronald Li, Dr. Yu Ying Ngan Ng, Chi Wing Ngan […]